Previous 10 | Next 10 |
AzurRx BioPharma (AZRX) said that its experimental therapy MS1819 led to clinically meaningful improvements in the primary efficacy endpoint in a Phase 2 trial for the treatment of severe exocrine pancreatic insufficiency ((EPI)) in patients with cystic fibrosis ((CF)). The multi-center study...
Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint Full top-line data expected in Q2 2021 DELRAY BEACH, Fla., May 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (&...
DELRAY BEACH, Fla., May 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) d...
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) d...
Delray Beach, Florida--(Newsfile Corp. - May 11, 2021) - AzurRx BioPharma (NASDAQ: AZRX) today announced that James Sapirstein, Chairman, President, and CEO will be attending the Q2 Virtual Investor Summit. About AzurRx BioPharma AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a cli...
This week's deep dive is on a small GI-focused biopharma concern located just to the north of me here in Miami. The company recently suffered a trial setback, but still has some 'shots on goal'. Full investment analysis is provided in the paragraphs below. For further detail...
Protalix BioTherapeutics (PLX) -43% on FDA rejection of experimental therapy for Fabry disease.Benitec Biopharma (BNTC) -22% after secures $13M capital via equity offering.Urban Tea (MYT) -13% on 1H earnings releasePinterest (PINS) -12% on Q1 earnings releas...
A study conducted by a group of researchers from the Louisiana State University School of Public Health and Medicine, led by professor of biostatistics Hui-Yi Lin, has discovered that sufficient levels of five antioxidants may decrease infection with the human papilloma virus (“HP...
Will Reopening Penny Stocks Continue to See Investor Interest? Reopening penny stocks have become extremely popular with investors over the past few months. Before we get into why let’s first define what a reopening penny stock is. This term applies to penny stocks that h...
AzurRx BioPharma (NASDAQ: AZRX) , a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. T...
News, Short Squeeze, Breakout and More Instantly...
AzurRx BioPharma Inc. Company Name:
AZRX Stock Symbol:
NASDAQ Market:
AzurRx BioPharma Inc. Website:
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (G...
Why Investors Are Watching These 3 Penny Stocks Right Now There are plenty of ways to find the best penny stocks to buy right now. And, one method that many penny stocks investors use is looking at what top investors are buying alongside other metrics. While this can be a good strat...
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...